EASD 2020 research news
An easy to digest guide to precision nutrition
Scientific session: Wednesday, September 23; 5:30 PM (CEST)
I love good food, and I am looking forward to learning what my gut and genes have to do with this.
Primary results of the EMPEROR-Reduced trial & DAPA-CKD trial
Endocrine exaptation is the order of the day, with glucose-lowering drugs being repurposed for vasculometabolic benefit. Can empagliflozin help reduce heart failure, and dapagliflozin help manage chronic kidney disease? Let's find out from two important sessions on EMPEROR-Reduced and DAPA-CKD.
This year’s EASD will see two new trials with SGLT2 inhibitors. The novelty here is that both these trials included people with and without diabetes. DAPA-CKD investigated the benefits of dapagliflozin in people with chronic kidney disease and EMPEROR-Reduced studying effects of empagliflozin on people with heart failure and reduced ejection fraction. These studies are likely to change practice in the management of both of these serious and common conditions.
The dawn of CV risk reduction in type 2 diabetes: 5 years of SGLT2i CV outcome trials
Symposium: Wednesday, 23 September; 8:30 AM (CEST)
I feel this program will be very important to help us all understand the past 5 years of SGLT2 inhibitors. We originally thought these were exciting agents for the management of diabetes – fast forward 5 years – we have seen benefit in CVOTs, heart failure trials, and more recently trials in CKD. While this is all very promising, understanding the “why or how” this is happening is important – welcome to the team cardiology and nephrology – together we achieve more for people living with diabetes… and even those without!
The LIBERATES Trial
improving gLucose control in patIents with diaBEtes following myocaRdial infArction: The role of a novEl glycaemic monitoring Strategy
Scientific session: Wednesday, September 23; 8:30 AM (CEST)
The LIBERATES trial results will reveal how important glucose monitoring is and how beneficial it is to achieve time in range, even after experiencing an acute complication like myocardial infarction.
OP 18: Unlocking the potential of digital health
Oral presentations: Wednesday, September 23; 10:15 AM (CEST)
Delivery of diabetes care, education, and support has certainly changed in the last 6 months – maybe it forced us into the future – but it will be a very long time before we return to our previous in-person model of care. Perhaps it is time to embrace virtual care as the way of the future. This session will help provide insight into successes and challenges with different models of virtual care delivery.
Do we need surveillance of the liver of type 2 diabetes patients?
Scientific session: Thursday, September 24; 5:30 PM (CEST)
Viscero-metabolic health is an upcoming field of diabetes, and hepatocrinology is emerging as a discipline of endocrinology. This symposium will help explain the need to focus on liver function in diabetes, and glucose metabolism in liver disease.
Michael Berger debate
ESC vs EASD/ADA-guidelines on diabetes and cardiovascular disease: Same evidence but different interpretations - who’s right?
Scientific session: Friday, September 25; 8:30 AM (CEST)
Nothing like a good debate! This one sets the cardiologists up against the diabetologists – they will discuss the relative merits of the divergent guidance from the ESC and EASD on the use of newer therapies to prevent cardiovascular disease in people with diabetes.
Semaglutide for the treatment of obesity (STEP-programme)
Scientific session: Friday, September 25; 12:15 PM (CEST)
Obesity is the heaviest obstacle for modern day endocrinology and metabolic medicine. Will semaglutide offer a small STEP, and a giant leap, on our journey to managing obesity?